RJA
BIIB icon

Robshaw & Julian Associates’s Biogen BIIB Stock Holding History

Robshaw & Julian Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,620
Closed -$1.59M – 45
2016
Q4 		$1.59M Hold
5,620
– – 1.18% 31
2016
Q3 		$1.76M Hold
5,620
– – 1.31% 31
2016
Q2 		$1.36M Sell
5,620
-345
-6% -$90.9K 1.04% 33
2016
Q1 		$1.55M Buy
5,965
+300
+5% +$79.2K 1.17% 32
2015
Q4 		$206K Buy
+5,665
New +$1.63M 0.16% 45

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Robshaw & Julian Associates's BIIB Position: Q1 2017 in Review

Robshaw & Julian Associates sold out of Biogen (BIIB) in Q1 2017, closing a stake of 5,620 shares — an estimated $1.59M sold.

Robshaw & Julian Associates first reported a position in BIIB in Q4 2015 and held it in 5 quarters. The position peaked at $1.76M in Q3 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • Robshaw & Julian Associates reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • Robshaw & Julian Associates sold 5,620 Biogen shares in Q1 2017, an estimated $1.59M.
  • Robshaw & Julian Associates first reported a position in Biogen in Q4 2015 and held it in 5 quarters.
  • Robshaw & Julian Associates's Biogen position peaked at $1.76M in Q3 2016.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Robshaw & Julian Associates's 13F filing for Q1 2017, filed 25 Apr 2017.